AR086399A1 - Composiciones estables de povidona-yodo con anti-inflamatorios esteroides o no-esteroides - Google Patents
Composiciones estables de povidona-yodo con anti-inflamatorios esteroides o no-esteroidesInfo
- Publication number
- AR086399A1 AR086399A1 ARP120101708A ARP120101708A AR086399A1 AR 086399 A1 AR086399 A1 AR 086399A1 AR P120101708 A ARP120101708 A AR P120101708A AR P120101708 A ARP120101708 A AR P120101708A AR 086399 A1 AR086399 A1 AR 086399A1
- Authority
- AR
- Argentina
- Prior art keywords
- steroids
- compositions
- stable compositions
- povidona
- yodo
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 150000003431 steroids Chemical class 0.000 title abstract 3
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 abstract 3
- 229920000153 Povidone-iodine Polymers 0.000 abstract 3
- 229960001621 povidone-iodine Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 abstract 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 abstract 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 abstract 1
- 229960004875 difluprednate Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001067 hydrocortisone acetate Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960001798 loteprednol Drugs 0.000 abstract 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 229960002800 prednisolone acetate Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161485475P | 2011-05-12 | 2011-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086399A1 true AR086399A1 (es) | 2013-12-11 |
Family
ID=47139697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101708A AR086399A1 (es) | 2011-05-12 | 2012-05-14 | Composiciones estables de povidona-yodo con anti-inflamatorios esteroides o no-esteroides |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150038473A1 (OSRAM) |
| EP (1) | EP2707006B1 (OSRAM) |
| JP (2) | JP6072009B2 (OSRAM) |
| KR (1) | KR101967938B1 (OSRAM) |
| CN (1) | CN103957922A (OSRAM) |
| AR (1) | AR086399A1 (OSRAM) |
| AU (3) | AU2012253335B2 (OSRAM) |
| BR (1) | BR112013028735A2 (OSRAM) |
| CA (1) | CA2835343A1 (OSRAM) |
| CL (1) | CL2013003016A1 (OSRAM) |
| CO (1) | CO6821949A2 (OSRAM) |
| EC (1) | ECSP13013069A (OSRAM) |
| MX (1) | MX360666B (OSRAM) |
| PE (1) | PE20141070A1 (OSRAM) |
| TW (2) | TWI632914B (OSRAM) |
| WO (1) | WO2012155062A1 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2665195B2 (ja) | 1995-05-19 | 1997-10-22 | 日本電気移動通信株式会社 | Ｍｃａシステムにおける移動局の個別番号表示方法 |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| TW201325601A (zh) * | 2011-09-16 | 2013-07-01 | Foresight Biotherapeutics Inc | 安定之普維酮－碘組成物 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2013166408A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| HK1208162A1 (en) | 2012-05-03 | 2016-02-26 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| US20150366879A1 (en) * | 2013-02-15 | 2015-12-24 | Senju Pharmaceutical Co., Ltd. | Difluprednate emulsion composition containing antimicrobial metal |
| MX368903B (es) | 2013-02-20 | 2019-10-21 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3062618B1 (en) | 2013-11-01 | 2020-02-05 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| EP3302426A4 (en) | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| BR112018016398A2 (pt) | 2016-02-18 | 2018-12-18 | Invirsa Inc | métodos para o uso de 5'-adenosina difosfato ribose (adpr) |
| MX385752B (es) | 2016-04-14 | 2025-03-18 | Azura Ophthalmics Ltd | Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfunción de las glándulas de meibomio. |
| MX2018013507A (es) * | 2016-05-05 | 2019-09-11 | Veloce Biopharma Llc | Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo. |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR101935250B1 (ko) * | 2017-07-04 | 2019-01-04 | 김대황 | 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물 |
| JP7242696B2 (ja) | 2018-03-27 | 2023-03-20 | インバーサ， インコーポレイテッド | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| CN115279458A (zh) | 2020-01-10 | 2022-11-01 | 阿祖拉眼科有限公司 | 组合物和敏感性说明 |
| CN113797163B (zh) * | 2020-06-17 | 2023-07-14 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂 |
| CN112305115B (zh) * | 2020-10-29 | 2022-08-23 | 诺峰药业(成都)有限公司 | 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法 |
| KR20220062790A (ko) | 2020-11-09 | 2022-05-17 | 정춘영 | 포비돈 아이오딘계 소독액 |
| CA3203779A1 (en) * | 2021-01-21 | 2022-07-28 | Joon Youb Lee | Ophthalmic composition |
| US20250281395A1 (en) * | 2021-01-22 | 2025-09-11 | Chengdu Ruimu Biopharmaceuticals Co., Ltd. | Ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis through eye drop administration |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3886268A (en) * | 1972-05-30 | 1975-05-27 | Synergistics | Iodophor-steroid compound pharmaceutical compositions |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| PT2291081T (pt) * | 2008-06-12 | 2020-09-10 | Takeda Pharmaceuticals Co | Iodopovidona, um novo conservante alternativo para composições oftálmicas |
| WO2011084473A1 (en) * | 2009-12-15 | 2011-07-14 | Foresight Biotherapeutics, Inc. | Non-irritating ophthalmic povidone-iodine compositions |
| TW201325601A (zh) * | 2011-09-16 | 2013-07-01 | Foresight Biotherapeutics Inc | 安定之普維酮－碘組成物 |
-
2012
- 2012-05-11 AU AU2012253335A patent/AU2012253335B2/en not_active Ceased
- 2012-05-11 WO PCT/US2012/037563 patent/WO2012155062A1/en not_active Ceased
- 2012-05-11 TW TW101116855A patent/TWI632914B/zh not_active IP Right Cessation
- 2012-05-11 CA CA2835343A patent/CA2835343A1/en not_active Abandoned
- 2012-05-11 US US14/117,086 patent/US20150038473A1/en not_active Abandoned
- 2012-05-11 EP EP12781920.9A patent/EP2707006B1/en active Active
- 2012-05-11 TW TW106131033A patent/TWI717552B/zh not_active IP Right Cessation
- 2012-05-11 BR BR112013028735A patent/BR112013028735A2/pt not_active Application Discontinuation
- 2012-05-11 CN CN201280034191.2A patent/CN103957922A/zh active Pending
- 2012-05-11 KR KR1020137032559A patent/KR101967938B1/ko not_active Expired - Fee Related
- 2012-05-11 PE PE2013002407A patent/PE20141070A1/es not_active Application Discontinuation
- 2012-05-11 JP JP2014510502A patent/JP6072009B2/ja not_active Expired - Fee Related
- 2012-05-11 MX MX2013012971A patent/MX360666B/es active IP Right Grant
- 2012-05-14 AR ARP120101708A patent/AR086399A1/es not_active Application Discontinuation
-
2013
- 2013-10-17 CL CL2013003016A patent/CL2013003016A1/es unknown
- 2013-12-09 EC ECSP13013069 patent/ECSP13013069A/es unknown
- 2013-12-09 CO CO13287528A patent/CO6821949A2/es not_active Application Discontinuation
-
2016
- 2016-09-02 AU AU2016222491A patent/AU2016222491A1/en not_active Abandoned
- 2016-12-22 JP JP2016248924A patent/JP6359619B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-17 AU AU2018203492A patent/AU2018203492A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2707006A4 (en) | 2014-09-24 |
| PE20141070A1 (es) | 2014-09-14 |
| AU2012253335A1 (en) | 2013-05-02 |
| KR20140045375A (ko) | 2014-04-16 |
| JP2017095474A (ja) | 2017-06-01 |
| AU2018203492A1 (en) | 2018-06-07 |
| JP6359619B2 (ja) | 2018-07-18 |
| TW201311256A (zh) | 2013-03-16 |
| MX360666B (es) | 2018-11-13 |
| EP2707006A1 (en) | 2014-03-19 |
| TW201811340A (zh) | 2018-04-01 |
| TWI632914B (zh) | 2018-08-21 |
| JP2014516954A (ja) | 2014-07-17 |
| KR101967938B1 (ko) | 2019-04-10 |
| AU2016222491A1 (en) | 2016-09-22 |
| BR112013028735A2 (pt) | 2017-12-05 |
| CL2013003016A1 (es) | 2014-05-02 |
| CN103957922A (zh) | 2014-07-30 |
| CO6821949A2 (es) | 2013-12-31 |
| EP2707006B1 (en) | 2019-07-03 |
| JP6072009B2 (ja) | 2017-02-01 |
| AU2012253335B2 (en) | 2016-08-04 |
| WO2012155062A1 (en) | 2012-11-15 |
| ECSP13013069A (es) | 2015-03-31 |
| TWI717552B (zh) | 2021-02-01 |
| CA2835343A1 (en) | 2012-11-15 |
| MX2013012971A (es) | 2013-12-12 |
| US20150038473A1 (en) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086399A1 (es) | Composiciones estables de povidona-yodo con anti-inflamatorios esteroides o no-esteroides | |
| WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| MX383208B (es) | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. | |
| MX2019000547A (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| CL2014000592A1 (es) | Composicion oftalmica de administracion topica que comprende povidona-yodo, esteroide, anestesico, reforzador de la penetracion, preservativo antimicrobiano, cosolvente/surfactante y agente de aumento de la viscosidad; y metodo de tratamiento y/o profilaxis de un trastorno oftalmico o una infeccion por microorganismos en el ojo. | |
| MX2016011132A (es) | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. | |
| WO2012009171A3 (en) | Compositions and methods of treatment of corneal endothelium disorders | |
| PE20141018A1 (es) | Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma tumores de celulas b | |
| BR112014008759A2 (pt) | tratamento de doença ocular | |
| MX2014010537A (es) | Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas. | |
| PH12017501300A1 (en) | Novel iodophor composition and methods of use | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| MX2016002408A (es) | Metodos para el tratamiento de trastornos oticos pediatricos. | |
| TR201900863T4 (tr) | Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması. | |
| WO2012090194A3 (en) | Compositions and methods for treating a skin disorder | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| PH12014501573A1 (en) | Topical pharmaceutical compositions comprising bexarotene and a corticosteroids | |
| CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
| MX2016010699A (es) | Composiciones y metodos para tratar neutropenia. | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
| EP4364810A3 (en) | Topical formulations and uses thereof | |
| BR112015019524A2 (pt) | tratamento de combinação | |
| PH12018500886A1 (en) | Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |